Clinical Practice and Management Flashcards

A 78-year-old male with persistent atrial fibrillation (CHA₂DS₂-VASc score of 4) is scheduled for a dual-chamber pacemaker implantation. He is currently on warfarin with a therapeutic INR. Based on the landmark BRUISE CONTROL trial, what is the most appropriate strategy for managing his anticoagulation around the time of surgery?

Answer: Continue uninterrupted warfarin, ensuring the INR is within the therapeutic range (2.0-3.0).

The BRUISE CONTROL trial demonstrated that continuing warfarin therapy was superior to bridging with heparin, resulting in a significant reduction in the incidence of clinically significant device pocket hematomas (3.5% vs. 16%). This practice avoids the increased bleeding risk associated with heparin bridging and the thromboembolic risk of stopping anticoagulation altogether.

A device manufacturer issues a notification for a specific model of ICD due to a software anomaly that could, in rare circumstances, fail to deliver therapy during a life-threatening arrhythmia. According to the FDA's medical device recall classifications, what is this situation most likely to be classified as?

Answer: A Class I recall, because there is a reasonable probability that use of the product will cause serious adverse health consequences or death.

A Class I recall is the most urgent classification. It is used in situations where there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. A failure to deliver life-saving ICD therapy falls squarely into this category.

A remote transmission from an asymptomatic 65-year-old patient with an ICD for primary prevention (ischemic cardiomyopathy, EF 30%) is flagged for a 12-beat run of non-sustained ventricular tachycardia (NSVT) at 155 bpm. The device functioned appropriately and did not deliver therapy. What is the most appropriate next step for the reviewing clinician?

Answer: Contact the patient to assess for symptoms and schedule a routine in-person follow-up.

Brief, asymptomatic, non-sustained VT is a common finding on device interrogations and does not typically warrant immediate or emergent action in a stable patient. The appropriate response is to correlate the arrhythmia with any potential symptoms, ensure the patient is otherwise stable, and schedule a routine follow-up to review device settings and overall clinical status. Urgent intervention is not indicated for this isolated finding.

During a complex ablation procedure requiring significant fluoroscopy time, which of the following actions is MOST effective for reducing the primary operator's radiation exposure, in accordance with ALARA (As Low As Reasonably Achievable) principles?

Answer: Using the lowest possible frame rate (pulse rate) for fluoroscopy.

Reducing the fluoroscopy frame rate (e.g., from 15 to 7.5 pulses per second) directly decreases the amount of radiation emitted per unit of time, significantly lowering the total dose to both the patient and staff. While distance and shielding are key ALARA principles, frame rate reduction offers one of the most substantial dose reductions that can be easily implemented. Maximizing magnification increases the radiation dose, and increasing the source-to-patient distance also increases patient dose.

During a transseptal puncture for a left atrial ablation, the patient suddenly becomes hypotensive (BP 85/50 mmHg), tachycardic, and their jugular venous pressure becomes markedly elevated. On the fluoroscopy monitor, the cardiac silhouette appears enlarged. This clinical presentation is most consistent with which procedural complication?

Answer: Cardiac tamponade.

The combination of hypotension, elevated jugular venous pressure, and tachycardia (with muffled heart sounds often noted on physical exam) is known as Beck's triad, a classic sign of cardiac tamponade. This life-threatening complication can occur if the needle or sheath perforates the atrial free wall during a transseptal puncture, causing blood to accumulate in the pericardial space.

Which of the following elements is NOT a mandatory component of the informed consent process for an electrophysiology procedure like a catheter ablation or device implant?

Answer: A guarantee of a successful outcome without complications.

The informed consent process must provide a comprehensive overview of the procedure, including its purpose, benefits, significant risks, and available alternatives. However, it is unethical and impossible to guarantee a specific outcome or a complication-free procedure. The consent process is about ensuring the patient understands the potential benefits and risks so they can make an autonomous decision, not about promising a certain result.